[1]. Notghi P, Khorrami S, Vazini H, Mordadi A, Hajiahmadi F, Soleimaniasl S, et al. Tumor Immunotherapy, History and Achievements.
[2]. Noori-Daloii MR, ed. Emery's elements of medical genetics. 8thed. Tehran,Iran: Jame-e-negar and Salemi Publication; 2017. [in Persian].
[3]. Noori-Daloii MR, Medical molecular genetics in third millennium. Tehran,Iran: Samer Publication; 2012. [in Persian].
[4]. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. 2015; 125(9):3335-7.
[5]. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. 2006; 26:154.
[6]. Cann SH, Van Netten J, Van Netten C. Dr William Coley and tumour regression: a place in history or in the future. 2003; 79(938):672-80.
[7]. Parish CR. biology c. Cancer immunotherapy: the past, the present and the future. 2003;81(2):106-13.
[8]. Noori-Daloii MR, Rahimi-Rad N, Kavoosi S. Immunotherapy Usingengineered T-Cells(Cars): A significant evolution in modern medical biotechnology. 2018. [in Persian]
[9]. Noori-Daloii MR, Rahimi-Rad N, Kavoosi S. Car T-cells: Novel targeted therapies in cancer. 2018. [in Persian]
[10].Drake CG, Jaffee E, Pardoll D. Mechanisms of immune evasion by tumors. 2006; 90:51-81.
[11].Chen K, Husain S, Marathe A, Haq M, Sciences H. Molecular Genetics of Cancer. 2018; 2(4):199-208.
[12].M Candeias S, S Gaipl U. The immune system in cancer prevention, development and therapy. 2016; 16(1):101-7.
[13].Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology: Elsevier Health Sciences; 1994.
[14].Sharabi A, Ying D, Thomas R, Klatzmann D, George C. Regulatory T cells in the treatment of disease. Nature Reviews Drug Discovery. 2018; 17:823-44.
[15].Schreiber R, Old L, Smyth M. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. 2011; 331(6024):1565-70.
[16].Grivennikov S, Greten F, Karin M. Immunity, inflammation, and cancer. 2010; 140(6):883-99.
[17].Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? 2001; 357(9255):539-45.
[18].Coussens L, Werb Z. Inflammation and cancer. 2002; 420(6917):860.
[19].Desmoulière A, editor Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. 2nd Scar meeting; 2008.
[20].Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. 2015; 125(9):3347-55.
[21].Taniguchi K, Wu L, Grivennikov S, De Jong P, Lian I, Yu F, et al. A gp130–Src–YAP module links inflammation to epithelial regeneration. 2015; 519(7541):57.
[22].Sakr W, Grignon D, Crissman J, Heilbrun L, Cassin B, Pontes J, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. 1994; 8(3):439-43.
[23].Nelson W, Angelo M. De Marzo and William B. 2003; 349(4):366-81.
[24].Hussain S, Hofseth L, Harris C. Radical causes of cancer. 2003; 3(4):276.
[25].Cerutti P, Amstad P. Inflammation and oxidative stress in carcinogenesis. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury: Springer; 1993. p. 387-90.
[26].Noori-Daloii MR, Hajifaraj-Tabrizi M. Cancer metastasis, genetic and microenvironmental factors of distant tissue: a review article. 2013; 70(11). [in Persian]
[27].Marvel D, Gabrilovich D. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. 2015; 125(9):3356-64.
[28].Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. 2015; 125(9):3365-76.
[29].Mundy-Bosse B, Lesinski G, Jaime-Ramirez A, Benninger K, Khan M, Kuppusamy P, et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. 2011.
[30].Brunet J, Denizot F, Luciani M, Roux-Dosseto M, Suzan M, Mattei M, et al. A new member of the immunoglobulin superfamily—CTLA-4. 1987; 328(6127):267.
[31].Walunas T, Lenschow D, Bakker C, Linsley P, Freeman G, Green J, et al. CTLA-4 can function as a negative regulator of T cell activation. 1994; 1(5):405-13.
[32].Waterhouse P, Penninger J, Timms E, Wakeham A, Shahinian A, Lee K, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. 1995; 270(5238):985-8.
[33].Leach D, Krummel M, Allison J. Enhancement of antitumor immunity by CTLA-4 blockade. 1996; 271(5256):1734-6.
[34].Buchbinder E, Hodi F. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. 2015; 125(9):3377-83.
[35].Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. 1992; 11(11):3887-95.
[36].Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. 1999; 5(12):1365.
[37].Freeman G, Long A, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. 2000; 192(7):1027-34.
[38].Dong H, Strome S, Salomao D, Tamura H, Hirano F, Flies D, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. 2002; 8(8):793.
[39].Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, McDermott D, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. 2012; 366(26):2443-54.
[40].Eshhar Z, Waks T, Gross G, Schindler D. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. 1993; 90(2):720-4.
[41].Brentjens R, Latouche J, Santos E, Marti F, Gong M, Lyddane C, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. 2003; 9(3):279.
[42].Kochenderfer J, Wilson W, Janik J, Dudley M, Stetler-Stevenson M, Feldman S, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19. 2010:blood-2010-04-281931.
[43].Kalos M, Levine B, Porter D, Katz S, Grupp S, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. 2011; 3(95):95ra73-95ra73.
[44].Grupp S, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold S, et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. 2013; 368(16):1509-18.
[45].Brentjens R, Davila M, Riviere I, Park J, Wang X, Cowell L, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. 2013; 5(177):177ra38-ra38.
[46].Melief C, Van Hall T, Arens R, Ossendorp F, VanderBurg S. Therapeutic cancer vaccines. 2015; 125(9):3401-12.
[47].Schumacher T. Neoantigens in cancer immunotherapy. Science. 2015; 348:69-74.
[48].Gubin M, Mardis E, Schreiber R. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015; 125:3413-21.
[49].Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, et al. Immune approaches to the treatment of breast cancer, around the corner? 2014; 16(1):204.
[50].Eno J. Immunotherapy Through the Years. 2017; 8(7):747.
[51].Mittendorf E, Singletary S. Breast cancer vaccines. Cancer. 2007; 110:1677-86.
.